A randomized, double-blind, placebo-controlled trial with a novel dual noradrenergic reuptake inhibitor (NARI) and 5-HT3 antagonist: Results of a phase II 8-week study in female patients with diarrhea predominant irritable bowel syndrome (D-IBS) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Paterson, William G
  • Sponger, Jonathon
  • O'Mahony, Michael
  • Reynolds, Richard P
  • Ganguli, Subhas Chandra
  • Feagan, Brian
  • Nurbhai, Suhail
  • Landau, Steven B

publication date

  • April 1, 2008